Novavax Inc (Novavax) is a biotechnology company that discovers, develops and commercializes vaccines to prevent a wide range of infectious diseases. The company develops genetically-engineered vaccine candidates harnessing three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. Its pipeline products include NVX-CoV2373 for coronavirus, NanoFlu for seasonal influenza, ResVax for respiratory syncytial syndrome and vaccines indicated for the prevention of Ebola virus, Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS). It is also developing proprietary immune-stimulating saponin-based adjuvants. The company operates research and manufacturing facilities in Gaithersburg, Maryland; Uppsala, Sweden; and Bohumil, Czech Republic. Novavax is headquartered in Gaithersburg, Maryland, the US.
Headquarters
United States of America
Address
21 Firstfield Road, Gaithersburg, Maryland, 20878
Website
www.novavax.com
Telephone
1 240 2682000
No of Employees
1,541
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
NVAX (NASD)
Revenue (2022)
$1.1B
141%
(2022 vs 2021)
EPS
XXX
Net Income (2022)
XXX
-316.9%
(2022 vs 2021)
Market Cap*
$1.0B
Net Profit Margin (2022)
XXX
-73.0%
(2022 vs 2021)
* As of and is in US$
Access premium data and analytics for Novavax Inc
Products and Services
| Products | Brands |
|---|---|
| Pipeline | NanoFlu |
| NVX-CoV2373 – Coronavirus | Matrix-M |
| NanoFlu - Seasonal Influenza Vaccine | ResVax |
| XXX | |
| XXX | |
| XXX |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2022 | Regulatory Approval | In December, the company announced Health Canada approved a supplement to a New Drug Submission (sNDS) for Nuvaxovid (COVID-19 Vaccine (Recombinant protein, Adjuvanted)) (NVX-CoV2373). |
| 2022 | Regulatory Approval | In July, the company received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) to provide a two-dose primary series for active immunization to prevent coronavirus disease 2019. |
| 2022 | Others | In May, the company announced the initiation of its Phase 3 strain change trial to determine if its Omicron variant specific vaccine, NVX-CoV2515. |
Competitor Comparison
| Key Parameters | Novavax Inc | Novartis AG | Merck & Co Inc | GSK plc | AstraZeneca Plc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | United States of America | United Kingdom | United Kingdom |
| City | Gaithersburg | Basel | Kenilworth | Brentford | Cambridge |
| State/Province | Maryland | - | New Jersey | - | Cambridgeshire |
| No. of Employees | 1,541 | 108,000 | 68,000 | 90,096 | 83,100 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| James F. Young, Ph.D. | Chairman | Executive Board | 2011 | 69 |
| John Jacobs | Chief Executive Officer; Director; President | Executive Board | 2023 | - |
| Jim Kelly | Treasurer; Executive Vice President; Chief Financial Officer | Senior Management | 2021 | 56 |
| Rick Crowley | Executive Vice President; Chief Operating Officer | Senior Management | 2020 | - |
| Biegie Lee | Senior Vice President; Chief Information Officer | Senior Management | 2020 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XX |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company Analytics
Contact the team or request a demo to find out how our data can drive your business forward